• Horizon’s GS null cell lines now include ProteoNic CHOGUN vector as standard
• Inclusion of vector provides customers with complete biomanufacturing platform
Cambridge, UK, 7 June 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies including bioproduction cell lines, today announces it has entered into a non-exclusive Licensing Agreement with ProteoNic B.V. to provide the CHOGUN expression vector to customers alongside Horizon’s HD-BIOP3 GS Null CHO cell line as standard, providing a powerful and complete biomanufacturing platform.
Morgan Hill, Ca, USA - 9 September 2015. Aragen Bioscience, Inc. (Aragen) announces that it has entered into an agreement with ProteoNic Biotechnology BV (ProteoNic) for the commercial use of ProteoNic’s 2G UNic™ recombinant protein production technology. Under the terms of the agreement, Aragen gains the rights to apply this technology to the development of recombinant cell lines with significantly enhanced commercial production levels compared to current methods. In combination with the value added services offered by Aragen, access to the technology will allow Aragen’s clients to increase manufacturing efficiency and reduce cost of goods for recombinant biologicals.
Leiden, the Netherlands, 23 January 2014 – ProteoNic BV, a leading provider of technology for recombinant protein production, will participate in an international consortium that has been awarded a EUR 7 million Framework Program 7 (FP7) Research Grant by the European Commission. The FP7 grant will support the development of novel enzymes for efficient production of antioxidants.
2G UNic™ vectors and plug-in elements for protein production
ProteoNic has relocated its headquarters, expanding its facilities at the Leiden Bio Science Park, the Netherlands
Leiden, Netherlands/Oxford, United Kingdom, March 7, 2013 – Dutch biotech company ProteoNic BV and Oxford Expression Technologies Ltd (OET), a leading provider of baculovirus-based protein expression products and services, have extended their partnership by signing a commercial license agreement. OET obtains the right to use ProteoNic’s UNic™ translation enhancing elements in its flashBAC™ system for third party recombinant protein production services. ProteoNic will provide technical support. Financial terms include upfront and royalty payments.
Both companies will be represented at BIO Europe Spring in Barcelona on March 11 -13 and are available for partnering meetings.